NEWS & MEDIA

Neovacs Announces Independent Data and Safety Monitoring Board Supports Continuation of Phase IIb Clinical Trial for IFNα Kinoid in Lupus

Paris, February 3, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces that it received a positive data review from the Independent Data and Safety Monitoring Board (IDSMB) that allows the Company to continue the Phase IIb clinical trial with lead product candidate, IFNα Kinoid for the treatment of Lupus.

Download pdf